Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
HOUSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) (Salarius or the Company) announces that on October...
Year: 2025
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108
PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD)...
Ardelyx to Report Third Quarter 2025 Financial Results on October 30, 2025
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a...
Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs
HOUSTON, TX, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”), the leader...
Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
ProQR to Participate in Upcoming Investor Conferences in October 2025
LEIDEN, Netherlands & CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated...
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission...
Auron Therapeutics to Participate in the 8th Annual Targeted Protein Degradation & Induced Proximity Summit
NEWTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Auron Therapeutics, a clinical-stage biotechnology company targeting cell-state plasticity to improve patient...
Wellgistics Health Announces Executive Management and Board Changes
TAMPA, FLORIDA / ACCESS Newswire / October 13, 2025 / Wellgistics Health, Inc. ("Wellgistics" or the "Company") (NASDAQ:WGRX), a leader...
Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be presented at an oral session on October 17,...
Medicus Pharma Ltd. to Present at The Maxim Growth Summit 2025
EXECUTIVE CHAIRMAN & CEO OF MEDICUS TO PARTICIPATE IN A FIRESIDE CHAT WITH EQUITY RESEARCH ANALYST PHILADELPHIA, PENNSYLVANIA / ACCESS...
HMNC Brain Health Presents New Analysis Supporting Rationale for Combining a Genetic Patient Selection Tool with a Vasopressin V1b Receptor Antagonist in the Treatment of Depression at ISCTM Conference in Amsterdam
Findings suggest a subset of Major Depressive Disorder patients may respond preferentially to vasopressin V1b receptor antagonismMUNICH, Oct. 13, 2025...
CS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment Offering
CHEYENNE, WYOMING / ACCESS Newswire / October 13, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) today announced the official launch of...
Collegium to Celebrate 10-Year Anniversary with Nasdaq Opening Bell Ringing
– Collegium to Ring Nasdaq Opening Bell on October 14, 2025 –STOUGHTON, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Collegium...
MDCE’s Infinite Auctions Announces Fall Flash Auction Featuring Jordan, LeBron, and Brady Amid AI Research Momentum
MESA, AZ / ACCESS Newswire / October 13, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), a diversified company advancing...
Hinge Bio Announces FDA Clearance of Investigational New Drug Application for HB2198, a Novel B cell-Depleting Agent, for Patients with Systemic Lupus Erythematosus and Lupus Nephritis
Phase 1 trial to investigate novel multi-specific HB2198 to treat B cell-mediated autoimmune disorders by targeting both CD19 and CD20...
SELLAS Life Sciences to Present In Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia at the European Society for Medical Oncology (ESMO) Congress 2025
Preclinical data support SLS009 as a monotherapy or in combination with venetoclax for the treatment of T-PLL, a rare and...
Cidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025
SAN DIEGO, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak® platform...
4DMT Advances 4D-710 to Phase 2 with Additional Funding and Support from the Cystic Fibrosis Foundation
Cystic Fibrosis Foundation to provide up to $11 million in additional funding to accelerate development of 4D-710 for cystic fibrosis,...
Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors
Appointment adds three decades of financial and operational leadership to Soleno’s BoardREDWOOD CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) --...